Mecasermin
Mecasermin , also known as recombinant human insulin-like growth factor-1, is a recombinant form of human insulin-like growth factor 1 which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome.
Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.
A related medication is mecasermin rinfabate, which is a combination of mecasermin, insulin-like growth factor binding protein-3, and insulin-like growth factor binding protein acid labile subunit as a ternary complex. The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.
